Supernus Pharmaceuticals (SUPN) FCF Margin (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of FCF Margin data on file, last reported at 9.19% in Q4 2025.

• FCF Margin for Q4 2025 came in at 9.19%, down 1619.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 6.4% (down 1947.0% YoY), and the FY2025 annual result was 6.4%, down 1947.0% from the prior year.
• FCF Margin rose to 9.19% in Q4 2025 per SUPN's latest filing, from 32.17% in the prior quarter.
• Over five years, FCF Margin peaked at 41.98% in Q2 2022 and troughed at 32.17% in Q3 2025.
• A 5-year average of 18.05% and a median of 24.3% in 2023 frame the typical range for FCF Margin.
• The sharpest annual moves came in 2024 and 2025: FCF Margin soared 3517 bps in 2024, then plunged 6252 bps in 2025.
• A 5-year view of FCF Margin shows it stood at 30.66% in 2021, then slumped by 46 bps to 16.57% in 2022, then soared by 65 bps to 27.38% in 2023, then declined by 7 bps to 25.38% in 2024, then tumbled by 64 bps to 9.19% in 2025.
• Business Quant data shows SUPN's FCF Margin at 9.19% in Q4 2025, 32.17% in Q3 2025, and 35.1% in Q2 2025.